bonartos 1178 mg filmsko obložene tablete
blue bio pharmaceuticals limited - glukozamin - filmsko obložena tableta - glukozamin 1178 mg / 1 tableta - glukozamin
bonartos 1178 mg filmsko obložene tablete
blue bio pharmaceuticals limited - glukozamin - filmsko obložena tableta - glukozamin 1178 mg / 1 tableta - glukozamin
glukozamin "pharma nord" 400 mg trde kapsule
pharma nord-mah - glukozamin - kapsula, trda - glukozamin 400 mg / 1 kapsula - glukozamin
glukozamin "pharma nord" 400 mg trde kapsule
pharma nord-mah - glukozamin - kapsula, trda - glukozamin 400 mg / 1 kapsula - glukozamin
dona 1178 mg prašek za peroralno raztopino
meda pharma gmbh & co. kg - glukozamin; natrijev klorid - prašek za peroralno raztopino - glukozamin 1178 mg / 1 vrečica natrijev klorid384 mg / 1 vrečica; natrijev klorid 384 mg / 1 vrečica - glukozamin
flexodon 1200 mg prašek za peroralno raztopino
angelini pharma d.o.o. - glukozamin - prašek za peroralno raztopino - glukozamin 1200 mg / 1 vrečica - glukozamin
flexodon 1200 mg prašek za peroralno raztopino
angelini pharma d.o.o. - glukozamin - prašek za peroralno raztopino - glukozamin 1200 mg / 1 vrečica - glukozamin
flexodon 1200 mg prašek za peroralno raztopino
angelini pharma d.o.o. - glukozamin - prašek za peroralno raztopino - glukozamin 1200 mg / 1 vrečica - glukozamin
lacosamide ucb
ucb pharma s.a. - lakosamid - epilepsije, delno - antiepileptics, - lacosamide ucb je označen kot monotherapy in adjunctive terapija pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev pri odraslih, mladostnikih in otrocih od 4 let z epilepsijo.
lacosamide adroiq
extrovis eu ltd. - lakosamid - epilepsija - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.